Impact of Endoluminal Radiofrequency Ablation on Immunity in Pancreatic Cancer and Cholangiocarcinoma.
antitumor immunity
cholangiocarcinoma
pancreatic ductal adenocarcinoma
radiofrequency ablation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Jun 2022
06 Jun 2022
Historique:
received:
16
05
2022
revised:
01
06
2022
accepted:
03
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Radiofrequency ablation (RFA) is a mini-invasive loco-regional ablation technique that is increasingly being used as a palliative treatment for pancreatic cancer and cholangiocarcinoma. Ablation-triggered immune system stimulation has been proposed as a mechanism behind the systemic effects of RFA. The aim of our study was to investigate the immune response to endoluminal biliary RFA. Peripheral blood samples were collected from patients with pancreatic cancer and cholangiocarcinoma randomised to receive endoluminal biliary radiofrequency ablation + stent (19 patients) or stent only (21 patients). We observed an early increase in IL-6 levels and a delayed increase in CXCL1, CXCL5, and CXCL11 levels as well as an increase in CD8+ and NK cells. However, these changes were not specific to RFA treatment. Explicitly in response to RFA, we observed a delayed increase in serum CXCL1 levels and an early decrease in the number of anti-inflammatory CD206+ blood monocytes. Our study provides the first evidence of endoluminal biliary RFA-based regulation of the systemic immune response in patients with pancreatic cancer and cholangiocarcinoma. These changes were characterised by a general inflammatory response. RFA-specific activation of the adaptive immune system was not confirmed.
Identifiants
pubmed: 35740353
pii: biomedicines10061331
doi: 10.3390/biomedicines10061331
pmc: PMC9219740
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Czech Grant Research Council
ID : 17-30281A
Références
Gastroenterol Res Pract. 2016;2016:9251375
pubmed: 27051417
Diagn Interv Imaging. 2017 Sep;98(9):651-659
pubmed: 28579522
Physiol Res. 2021 Nov 29;70(5):709-721
pubmed: 34505523
Ther Adv Med Oncol. 2020 Sep 10;12:1758835920953728
pubmed: 32973929
Oncogenesis. 2020 Jul 6;9(7):63
pubmed: 32632106
Pancreas. 2006 Jan;32(1):22-8
pubmed: 16340740
World J Gastroenterol. 2020 May 7;26(17):2040-2048
pubmed: 32536773
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
World J Gastroenterol. 2004 Apr 15;10(8):1137-40
pubmed: 15069713
Langenbecks Arch Surg. 2013 Jan;398(1):63-9
pubmed: 23053459
Cancer Res. 2006 Jan 15;66(2):1139-46
pubmed: 16424051
Korean J Radiol. 2008 Sep-Oct;9(5):470-2
pubmed: 18838859
Oncoimmunology. 2019 Jan 10;8(3):1550342
pubmed: 30723580
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Pancreatology. 2021 Oct;21(7):1342-1348
pubmed: 34215498
Endosc Int Open. 2019 Oct;7(10):E1293-E1300
pubmed: 31595223
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Cancer Res. 2004 Jun 1;64(11):4024-9
pubmed: 15173017
Anticancer Res. 2015 May;35(5):2961-7
pubmed: 25964582
Nature. 2004 Sep 23;431(7007):405-6
pubmed: 15385993
Surg Endosc. 2021 Jan;35(1):63-73
pubmed: 32488654
J Urol. 2003 Jul;170(1):178-9
pubmed: 12796677
Endoscopy. 2018 Aug;50(8):751-760
pubmed: 29342492
Cancer Res. 2003 Oct 1;63(19):6496-500
pubmed: 14559842
Gastrointest Endosc. 2018 Apr;87(4):944-951.e1
pubmed: 29108980
Radiology. 2009 Apr;251(1):58-66
pubmed: 19251937
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Endocr Relat Cancer. 2010 Oct 05;17(4):929-40
pubmed: 20702723
Int J Clin Oncol. 2003 Oct;8(5):332-5
pubmed: 14586761
Cell Stress Chaperones. 2011 Sep;16(5):495-504
pubmed: 21442384
Eur Surg Res. 2002 Sep-Oct;34(5):357-63
pubmed: 12364820
Hum Immunol. 2009 Jul;70(7):477-86
pubmed: 19332094
Nat Commun. 2019 Nov 28;10(1):5421
pubmed: 31780645
Int J Oncol. 2004 Mar;24(3):609-13
pubmed: 14767545
Int J Oncol. 2019 Sep;55(3):684-696
pubmed: 31322183
Gastrointest Endosc. 2020 Dec;92(6):1204-1212.e1
pubmed: 32437711
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Med Oncol. 2018 Oct 4;35(12):151
pubmed: 30284649
Front Oncol. 2020 Jan 10;9:1515
pubmed: 31998654
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Cell Death Dis. 2018 Aug 29;9(9):880
pubmed: 30158589
Front Oncol. 2020 Sep 04;10:1308
pubmed: 33014771
Pancreatology. 2017 Nov - Dec;17(6):962-966
pubmed: 29037917
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33115942
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
Gastrointest Endosc. 2021 Jul;94(1):91-100.e2
pubmed: 33359435
Radiology. 2015 Aug;276(2):416-25
pubmed: 25822472
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
World J Gastrointest Oncol. 2021 Oct 15;13(10):1383-1396
pubmed: 34721772
Semin Immunol. 2014 Feb;26(1):38-47
pubmed: 24602448
BJU Int. 2012 Sep;110(6 Pt B):E281-6
pubmed: 22612555
Annu Rev Immunol. 2002;20:395-425
pubmed: 11861608